Ozempic (semaglutide) shortage collection
Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.
Type
Topics
- Shortages (10)
- Prescription medicines (4)
- Advertising (3)
- Alert/Advisory (3)
- Medicines safety (3)
- Regulatory compliance (3)
- Weight loss products (3)
- Import and export (2)
- Therapeutic goods regulation (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Legislation (1)
- Manufacturing (1)
- Safety (1)
Read current information and updates at:
About the Ozempic (semaglutide) shortage 2022 and 2024
About the Trulicity (dulaglutide) shortage 2022 and 2023
The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout the rest of the year and into 2024 will be limited. Currently we are asking health professionals not to prescribe Ozempic to new patients to conserve supply for patients who are already stabilised on this medicine and who do not have suitable alternatives.
Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.
Collection content
- New semaglutide product becomes availableMedicine shortage alertsPharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.
- What you need to know about compounded weight-loss medicinesBlogSome online health clinics are advertising and selling compounded medicines. However, it is important to know that compounded products are not identical to TGA approved products.
- Compounding safety information: semaglutide-like productsSafety alertsWe are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.
- Shortage of Mounjaro (tirzepatide) injectionsMedicine shortage alertsThe availability of all strengths of Mounjaro (tirzepatide) will be limited until 31 August 2024, due to unexpected high demand. Patients and healthcare professionals should check the Medicine Shortage Reports Database for the latest supply information.
- Update: Prescribers advised not to start new patients on OzempicMedicine shortage alertsRead advice about not prescribing Ozempic to new patients unless there are no suitable alternatives or there is a compelling clinical reason.
- Ozempic (semaglutide) supply updateMedicine shortage alertsThe supply of Ozempic (semaglutide) in Australia is improving however the shortage continues. Stay updated about how the shortage impacts you.
- Counterfeit semaglutide vialsSafety alertsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.
- Consumers warned about Ozempic scamsMedia releasesThe TGA is aware of several scams targeting consumers seeking semaglutide (Ozempic). Consumers are strongly advised not to use products unless they have come from a trusted source.
- Limited Ozempic supplies to commence distribution in AustraliaNewsSupplies of Ozempic (semaglutide) have begun distribution in Australia but will remain quite limited for some time.
- A warning that advertising Ozempic (semaglutide) is prohibitedNewsA warning to social media influencers and advertisers not to advertise this prescription medicine.